EGEGazette
Live
Houthis Accuse Saudi Arabia of 28 Airstrikes in 24 Hours; U.S. Intelligence Chief Visits CairoWashington Warns Citizens of Unexpected Escalation in Middle EastIran Says Strait of Hormuz Will Stay Closed Until US Meets Its ConditionsTrump faces dual setback as U.S. courts block voting and immigration restrictionsLawsuit Filed Against Trump and His Company Over Paid Early Access Service to His PostsTrump Renews Bid to Restrict Birthright Citizenship Through Curbing "Birth Tourism"Trump Cuts Camp David Vacation Short Amid Middle East Escalation WarningsTrump Cuts Short Vacation, Returns to White House as US Issues "Possible Escalation" Warning in Middle EastReporters From CNN, MS NOW and Politico Denied White House Access After Trump BanFederal Immigration Agent Shoots and Injures Man in Austin, TexasPowerful Explosions Reported in Syria's Aleppo CountrysideSix Pakistani soldiers, including two officers, killed in clash near Afghan border
businessReported

Novartis shares fall 10% after three drug trial setbacks

The pharmaceutical company's stock dropped sharply Tuesday following disappointing results from trials including its del-desiran drug.

· 1 min read · language: en
Article image
CNBC — Top News

Novartis shares fell 10% on Tuesday after the company reported setbacks in three drug trials, including disappointing results from its del-desiran program, according to CNBC.

The trial failures prompted investor concern about the company's pipeline and near-term revenue prospects.

Sources

EGazette summarizes reporting from multiple sources; follow the links for the originals.

Related articles

Comments

Sign in to join the conversation.

Forgot password?

No account?

Loading comments…